grant guidelines
The goal of the grant process is a serious review of creative new directions in clinical and/or translational research and in need of seed funding. Proposals are invited by our Executive Board of Scientific Advisors, rather than accepted as unsolicited requests. The Scientific Advisors generally review proposals in the summer, following invited submissions in May and early June.
There is no set format, but the Foundation generally requests a brief project narrative, lay language summary suitable for public use, annual budget (no more than $225,000 initially, with a maximum of 20% in indirect costs) and budget narrative, with the total not to exceed five pages.
Considerable latitude is given to the investigators in terms of the work proposed. Both the Board of Directors and the Scientific Advisors concur that some of the most important advances in understanding the disease will most likely occur by enabling brilliant minds to pursue some of their most creative theories.
The Foundation's Executive Board of Scientific Advisors is comprised of the following breast cancer research leaders:
- Larry Norton, MD (Chairman), Deputy Physician-in-Chief and Director of Breast Cancer Programs, Memorial Sloan-Kettering Cancer Center, New York, NY
- Nancy Davidson, MD, Director of the University of Pittsburgh Cancer Institute, Pittsburgh, PA
- Peter Greenwald, MD, Dr.PH, Associate Director for Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD
- Gabriel N. Hortobagyi, MD, FACP, Professor of Medicine and Chairman, Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
Working closely with the Executive Board is a Scientific Advisory Committee, comprised of the following:
- Clifford Hudis, MD (Chairman), Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY
- Patricia A. Ganz, MD, Professor, Schools of Medicine and Public Health; Director, Cancer Prevention & Control Research, University of California, Los Angeles, CA
- Judy E. Garber, MD, MPH, Director, Cancer Risk & Prevention Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
- Lajos Pusztai, MD, D.Phil, Associate Professor of Medicine, Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
- Vered Stearns, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
Grants are awarded for a period covering October 1 - September 30, and are paid in two installments. All grantees are required to submit two progress reports; one by January 31 and the second by May 31. Receipt of the second installment of the year's grant is contingent upon review of the submitted reports and a recommendation from the Scientific Advisors.
Grants are generally awarded once a year, for a one-year duration beginning October 1. Pending satisfactory progress and continued need, grants may be renewed for at least a second year. First-year grants are generally at the level of $200,000, with renewed grants not to exceed $250,000. These figures include indirect costs, which BCRF limits to no more than 20% of direct costs.
|
